Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Nov 4;64(6):859–864. doi: 10.1136/ard.2004.024463

A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis

A Fraser 1, A W R van Kuijk 1, R Westhovens 1, Z Karim 1, R Wakefield 1, A Gerards 1, R Landewe 1, S Steinfeld 1, P Emery 1, B Dijkmans 1, D Veale 1
PMCID: PMC1755527  PMID: 15528283

Abstract

Objectives: To evaluate the safety and efficacy of adding ciclosporin A (CSA) to the treatment of patients with psoriatic arthritis (PsA) demonstrating an incomplete response to methotrexate (MTX) monotherapy.

Methods: In a 12 month, randomised, double blind, placebo controlled trial at five centres in three countries, 72 patients with active PsA with an incomplete response to MTX were randomised to receive either CSA (n = 38) or placebo (n = 34). Patients underwent full clinical and radiological assessment and, in addition, high resolution ultrasound (HRUS) was performed at one centre. An intention to treat (last observation carried forward) analysis was employed.

Results: Some significant improvements were noted at 12 months in both groups. However, in the active but not the placebo arm there were significant improvements in swollen joint count, mean (SD), from 11.7 (9.7) to 6.7 (6.5) (p<0.001) and C reactive protein, from 17.4 (14.5) to 12.7 (14.3) mg/l (p<0.05) as compared with baseline. The Psoriasis Area and Severity Index (PASI) score improved in the active group (2 (2.3) to 0.8 (1.3)) as compared with placebo (2.2 (2.7) to 1.9 (2.8)), p<0.001, and synovitis detected by HRUS (33 patients, 285 joints) was reduced by 33% in the active group compared with 6% in the placebo group (p<0.05). No improvement in Health Assessment Questionnaire or pain scores was detected.

Conclusions: Synovitis detected by HRUS was significantly reduced. Combining CSA and MTX treatment in patients with active PsA, and a partial response to MTX, significantly improves the signs of inflammation but not pain or quality of life.

Full Text

The Full Text of this article is available as a PDF (103.8 KB).

Figure 1.

Figure 1

Open in a new tab

 Changes in clinical, biochemical, and radiological measurements between baseline and 48 weeks. Significant changes from baseline are indicated (*p<0.05 and **p<0.001 for the active group; †p<0.05 and ††p<0.001 for the placebo group).

Figure 2.

Figure 2

Open in a new tab

 Percentage of joints with synovitis detectable by HRUS from baseline to 48 weeks. *p<0.05.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLACK R. L., O'BRIEN W. M., VANSCOTT E. J., AUERBACH R., EISEN A. Z., BUNIM J. J. METHOTREXATE THERAPY IN PSORIATIC ARTHRITIS; DOUBLE-BLIND STUDY ON 21 PATIENTS. JAMA. 1964 Sep 7;189:743–747. [PubMed] [Google Scholar]
  2. Backhaus M., Kamradt T., Sandrock D., Loreck D., Fritz J., Wolf K. J., Raber H., Hamm B., Burmester G. R., Bollow M. Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum. 1999 Jun;42(6):1232–1245. doi: 10.1002/1529-0131(199906)42:6<1232::AID-ANR21>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  3. Clark C. M., Kirby B., Morris A. D., Davison S., Zaki I., Emerson R., Saihan E. M., Chalmers R. J., Barker J. N., Allen B. R. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol. 1999 Aug;141(2):279–282. doi: 10.1046/j.1365-2133.1999.02976.x. [DOI] [PubMed] [Google Scholar]
  4. Espinoza L. R., Zakraoui L., Espinoza C. G., Gutiérrez F., Jara L. J., Silveira L. H., Cuéllar M. L., Martínez-Osuna P. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol. 1992 Jun;19(6):872–877. [PubMed] [Google Scholar]
  5. Fearon Ursula, Griosios Konstantina, Fraser Alexander, Reece Richard, Emery Paul, Jones Pamela F., Veale Douglas J. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol. 2003 Feb;30(2):260–268. [PubMed] [Google Scholar]
  6. Felson D. T., Anderson J. J., Boers M., Bombardier C., Chernoff M., Fried B., Furst D., Goldsmith C., Kieszak S., Lightfoot R. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993 Jun;36(6):729–740. doi: 10.1002/art.1780360601. [DOI] [PubMed] [Google Scholar]
  7. FitzGerald O., Kane D. Clinical, immunopathogenic, and therapeutic aspects of psoriatic arthritis. Curr Opin Rheumatol. 1997 Jul;9(4):295–301. doi: 10.1097/00002281-199707000-00004. [DOI] [PubMed] [Google Scholar]
  8. Fraser Alexander, Fearon Ursula, Billinghurst R. Clark, Ionescu Mirela, Reece Richard, Barwick Thomas, Emery Paul, Poole A. Robin, Veale Douglas J. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum. 2003 Nov;48(11):3085–3095. doi: 10.1002/art.11331. [DOI] [PubMed] [Google Scholar]
  9. Fredriksson T., Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244. doi: 10.1159/000250839. [DOI] [PubMed] [Google Scholar]
  10. Fries J. F., Spitz P. W., Young D. Y. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982 Sep-Oct;9(5):789–793. [PubMed] [Google Scholar]
  11. Gladman D. D., Shuckett R., Russell M. L., Thorne J. C., Schachter R. K. Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med. 1987 Feb;62(238):127–141. [PubMed] [Google Scholar]
  12. Gladman D. D., Stafford-Brady F., Chang C. H., Lewandowski K., Russell M. L. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990 Jun;17(6):809–812. [PubMed] [Google Scholar]
  13. Gladman Dafna D. Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum. 2003 Aug;33(1):29–37. doi: 10.1053/sarh.2002.50024. [DOI] [PubMed] [Google Scholar]
  14. Grassi W., Lamanna G., Farina A., Cervini C. Synovitis of small joints: sonographic guided diagnostic and therapeutic approach. Ann Rheum Dis. 1999 Oct;58(10):595–597. doi: 10.1136/ard.58.10.595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gupta A. K., Matteson E. L., Ellis C. N., Ho V. C., Tellner D. C., Voorhees J. J., McCune W. J. Cyclosporine in the treatment of psoriatic arthritis. Arch Dermatol. 1989 Apr;125(4):507–510. [PubMed] [Google Scholar]
  16. Heydendael Vera M. R., Spuls Phyllis I., Opmeer Brent C., de Borgie Corianne A. J. M., Reitsma Johannes B., Goldschmidt Wouter F. M., Bossuyt Patrick M. M., Bos Jan D., de Rie Menno A. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003 Aug 14;349(7):658–665. doi: 10.1056/NEJMoa021359. [DOI] [PubMed] [Google Scholar]
  17. Iurlaro M., Vacca A., Minischetti M., Ribatti D., Pellegrino A., Sardanelli A., Giacchetta F., Dammacco F. Antiangiogenesis by cyclosporine. Exp Hematol. 1998 Dec;26(13):1215–1222. [PubMed] [Google Scholar]
  18. Kane D., Stafford L., Bresnihan B., FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003 Oct 1;42(12):1460–1468. doi: 10.1093/rheumatology/keg384. [DOI] [PubMed] [Google Scholar]
  19. Kokelj F., Lavaroni G., Stinco G. Psoriatic arthritis treated with cyclosporin A. Allerg Immunol (Paris) 1992 Dec;24(10):393–394. [PubMed] [Google Scholar]
  20. Kragballe K., Zachariae E., Zachariae H. Methotrexate in psoriatic arthritis: a retrospective study. Acta Derm Venereol. 1983;63(2):165–167. [PubMed] [Google Scholar]
  21. Larsen A., Dale K., Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977 Jul;18(4):481–491. doi: 10.1177/028418517701800415. [DOI] [PubMed] [Google Scholar]
  22. Little Chris B., Hughes Clare E., Curtis Clare L., Jones Simon A., Caterson Bruce, Flannery Carl R. Cyclosporin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilage. Arthritis Rheum. 2002 Jan;46(1):124–129. doi: 10.1002/1529-0131(200201)46:1<124::aid-art10121>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  23. Lorenz Hanns-Martin. T-cell-activation inhibitors in rheumatoid arthritis. BioDrugs. 2003;17(4):263–270. doi: 10.2165/00063030-200317040-00005. [DOI] [PubMed] [Google Scholar]
  24. Mahrle G., Schulze H. J., Bräutigam M., Mischer P., Schopf R., Jung E. G., Weidinger G., Färber L. Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study. Br J Dermatol. 1996 Nov;135(5):752–757. [PubMed] [Google Scholar]
  25. Mazzanti G., Coloni L., De Sabbata G., Paladini G. Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study. Acta Derm Venereol Suppl (Stockh) 1994;186:116–117. [PubMed] [Google Scholar]
  26. Riccieri V., Sili Scavalli A., Spadaro A., Bracci M., Taccari E., Zoppini A. Short-term "cyclosporin A" therapy for psoriatic arthritis. Acta Derm Venereol Suppl (Stockh) 1994;186:94–95. [PubMed] [Google Scholar]
  27. Salvarani C., Macchioni P., Olivieri I., Marchesoni A., Cutolo M., Ferraccioli G., Cantini F., Salaffi F., Padula A., Lovino C. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol. 2001 Oct;28(10):2274–2282. [PubMed] [Google Scholar]
  28. Spadaro A., Riccieri V., Sili-Scavalli A., Sensi F., Taccari E., Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol. 1995 Sep-Oct;13(5):589–593. [PubMed] [Google Scholar]
  29. Tugwell P., Pincus T., Yocum D., Stein M., Gluck O., Kraag G., McKendry R., Tesser J., Baker P., Wells G. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med. 1995 Jul 20;333(3):137–141. doi: 10.1056/NEJM199507203330301. [DOI] [PubMed] [Google Scholar]
  30. Veale D., Rogers S., Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol. 1994 Feb;33(2):133–138. doi: 10.1093/rheumatology/33.2.133. [DOI] [PubMed] [Google Scholar]
  31. Wagner S. A., Peter R. U., Adam O., Ruzicka T. Therapeutic efficacy of oral low-dose cyclosporin A in severe psoriatic arthritis. Dermatology. 1993;186(1):62–67. doi: 10.1159/000247305. [DOI] [PubMed] [Google Scholar]
  32. Willkens R. F., Williams H. J., Ward J. R., Egger M. J., Reading J. C., Clements P. J., Cathcart E. S., Samuelson C. O., Jr, Solsky M. A., Kaplan S. B. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984 Apr;27(4):376–381. doi: 10.1002/art.1780270403. [DOI] [PubMed] [Google Scholar]
  33. Wong K., Gladman D. D., Husted J., Long J. A., Farewell V. T. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997 Oct;40(10):1868–1872. doi: 10.1002/art.1780401021. [DOI] [PubMed] [Google Scholar]
  34. Zachariae H., Zachariae E. Methotrexate treatment of psoriatic arthritis. Acta Derm Venereol. 1987;67(3):270–273. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES